微创与开腹肝切除治疗结直肠癌肝转移的系统评价与荟萃分析
该系统评价与荟萃分析比较了微创与开腹肝切除治疗可切除结直肠癌肝转移的疗效与安全性,纳入35项研究。分期切除中,微创组并发症更少、住院时间更短,肿瘤学结局相似;同期切除中,微创组出血量和住院时间更优。
要点
- 微创肝切除治疗结直肠癌肝转移的肿瘤学结局与开腹相似。
- 分期切除时微创组Clavien-Dindo III级并发症更少,住院时间更短。
- 同期切除时微创组出血量和住院时间更优。
核心结论
- 现有证据表明微创与开腹肝切除治疗结直肠癌肝转移的肿瘤学结局相似。
- 微创肝切除在分期和同期切除中均缩短住院时间、减少出血和并发症。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase、Google Scholar、Cochrane CENTRAL、ICTRP和ClinicalTrials.gov。
- 纳入2000年1月至2020年9月发表的随机对照试验和非随机比较研究,共35项研究。
- 分期切除纳入3项随机对照试验和20项观察性研究;同期切除纳入12项观察性研究。
- 采用随机效应模型,效应量为风险比和均数差。
主要发现
- 分期切除中,随机对照试验数据显示微创与开腹组1年无病生存率相似(RR 1.03,95%CI 0.70-1.50)。
- 分期切除中,随机对照试验数据显示微创与开腹组5年总生存率相似(RR 1.04,95%CI 0.84-1.28)。
- 分期切除中,微创组Clavien-Dindo III级并发症更少(RR 0.62,95%CI 0.38-1.00),住院时间更短(MD -6.6天,95%CI -10.2至-3.0)。
- 同期切除中,微创与开腹组在1年无病生存率、5年总生存率、并发症、R0切除率和输血方面无差异证据。
- 同期切除中,微创组出血量更少(MD -177.35 mL,95%CI -273.17至-81.53),住院时间更短(MD -3.0天,95%CI -3.82至-2.17)。
临床怎么用
- 对于可切除的结直肠癌肝转移,微创肝切除可作为开腹手术的替代选择。
- 微创肝切除在分期和同期切除中均可能减少并发症和缩短住院时间。
局限性
- 同期切除的证据仅来自观察性研究,可能存在选择偏倚。
- 分期切除中随机对照试验数量有限,部分结局证据质量可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While surgical resection has a demonstrated utility for patients with colorectal liver metastases (CRLM), it is unclear whether minimally invasive surgery (MIS) or an open approach should be used. This review sought to assess the efficacy and safety of MIS versus open hepatectomy for isolated, resectable CRLM when performed separately from (Key Question (KQ) 1) or simultaneously with (KQ2) the resection of the primary tumor. METHODS: PubMed, Embase, Google Scholar, Cochrane CENTRAL, International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov databases were searched to identify both randomized controlled trials (RCTs) and non-randomized comparative studies published during January 2000-September 2020. Two independent reviewers screened literature for eligibility, extracted data from included studies, and assessed internal validity using the Cochrane Risk of Bias 2.0 Tool and the Newcastle-Ottawa Scale. A random-effects meta-analysis was performed using risk ratios (RR) and mean differences (MD). RESULTS: From 2304 publications, 35 studies were included for meta-analysis. For staged resections, three RCTs and 20 observational studies were included. Data from RCTs indicated MIS having similar disease-free survival (DFS) at 1-year (RR 1.03, 95%CI 0.70-1.50), overall survival (OS) at 5-years (RR 1.04, 95%CI 0.84-1.28), fewer complications of Clavien-Dindo Grade III (RR 0.62, 95%CI 0.38-1.00), and shorter hospital length of stay (LOS) (MD -6.6 days, 95%CI -10.2, -3.0). For simultaneous resections, 12 observational studies were included. There was no evidence of a difference between MIS and the open group for DFS-1-year, OS-5-year, complications, R0 resections, blood transfusions, along with lower blood loss (MD -177.35 mL, 95%CI -273.17, -81.53) and shorter LOS (MD -3.0 days, 95%CI -3.82, -2.17). CONCLUSIONS: Current evidence regarding the optimal approach for CRLM resection demonstrates similar oncologic outcomes between MIS and open techniques, however MIS hepatectomy had a shorter LOS, lower blood loss and complication rate, for both staged and simultaneous resections.
引用
- Ozair A, Collings A, Adams AM, et al. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis. Surg Endosc. 2022. PMID: 36138246. doi:10.1007/s00464-022-09612-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。